Find generic entry opportunities
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension|
|Abstract:||The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.|
|Inventor(s):||Stjernschantz; Johan Wilhelm (Uppsala, SE), Resul; Bahram (Uppsala, SE)|
|Assignee:||Pharmacia & Upjohn Aktiebolag (Stockholm, SE)|
|Filing Date:||May 10, 1999|
|Claims:||1. A therapeutic composition for topical treatment of ocular hypertension containing a prostaglandin PGF in an amount sufficient to reduce intraocular pressure without causing substantial intraocular irritation, and an ophthamologically compatible vehicle, in which the alpha chain of the prostaglandin comprises a chain having the structure |
CH.sub.2 --CH.dbd.CH--CH.sub.2 --CH.sub.2 --CH.sub.2 --COOR.sub.1, wherein R.sub.1 is an alkyl group, and in which the omega chain of the prostaglandin has the formula
C is a carbon atom (the number according to standard prostaglandin nomenclature being indicated by the subscript);
B is a single bond, double bond or triple bond;
D is a subchain of 2-5 carbon atoms and 1-2 heteroatoms selected from the group consisting of O, N and S, having a substituent on each carbon atom selected from the group consisting of a hydrogen atom, an alkyl group, oxo group and a hydroxyl group; and
R.sub.2 is a phenyl group substituted with a trifluoromethyl group.
2. The therapeutic composition according to claim 1 wherein R.sub.1 is a butyl group.
3. The therapeutic composition according to claim 1 wherein the prostaglandin is a PGF.sub.2-alpha.
4. The therapeutic composition according to claim 2 wherein the prostaglandin is a PGF.sub.2-alpha.